EGFR and colorectal cancer: EGFR and KRAS mutation status are widely used in lung and colorectal cancer, respectively.8,9,12,13 In contrast, EGFR amplification and overexpression in tissue have not been well established as reliable biomarkers for anti-EGFR agents, (selected studies that investigated EGFR amplification/overexpression as a predictive marker for anti-EGFR therapies are summarized in the Data Supplement)11,14-19.